Teduglutide

Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis^[1][2][3][4].
In Vitro: Teduglutide (2.5 μM, 36 h) can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 in human hepatic stellate cells^[4].
Teduglutide can increase the proliferation of all intestinal segment epithelial cells and reduce cell apoptosis in the short intestine newborn piglet model^[5].
In Vivo: Teduglutide (0.1 mg/kg; twice daily; 2 weeks; s.c.) can alleviate intestinal dysfunction and nucleotide oligomeric domain 2 (Nod2) dysfunction induced intestinal failure in cecectomy mice^[1].
Teduglutide (200 μg/kg; twice daily; 10 days; s.c.) has anti apoptotic and antioxidant activities in mice with lung injury^[2].
Teduglutide (5 μg; once daily; 4 weeks; i.p.) can improve obesity related neuroinflammation, central stress, and cell apoptosis in mice fed a high-fat diet^[3].
Teduglutide (0.05 mg/kg; once daily; 4 weeks; i.p.) improves liver inflammation and fibrosis in a Mdr2 mouse model of sclerosing cholangitis by activating NR4a1/nur77 in hepatic stellate cells and intestinal FXR signaling^[4].